Biosystems International
Protein Biomarkers for Alzheimer's Predicted to Represent Cumulative $9B Market Over Next Decade
Premium
The figure comes from a report commissioned by proteomics firm Proteome Sciences, which, like a number of other protein biomarker firms including Quanterix, Rules-Based Medicine, and NextGen Sciences, has made AD a significant focus of its R&D and commercialization efforts.
BSI Partnering with Pharnext on $14.2M Initiative to Develop Biomarkers and Therapeutics for AD
Premium
Funded by the French innovation agency OSEO, the collaboration calls for the companies to develop a prototype blood-based protein biomarker test for Alzheimer's disease as well as a therapeutic for the disease and a companion diagnostic.
BSI Merges with MBC to Secure Access to Nanoarray Technology and New Academic and Pharma Markets
Premium
The merger will give Biosystems International access to MicroBioChips' nanoarray technology and its sales and marketing resources, which are expected to help the company establish new relationships with university-based proteomics laboratories and pharma and biotech firms.
The Paris-based firms earlier this year announced a partnership to develop monoclonal antibody microarrays that combine BSI's antibodies with MBC's microarray platform.
Biosystems International, MicroBioChips to Merge
The firms will combine Biosystems International's monoclonal antibody proteomics process with MBC's microarray technology.
Jul 23, 2010
Jul 19, 2010